PRVL - Prevail's gene therapy Orphan drug in Europe for a type of dementia

The European Commission has designated orphan designation to Prevail Therapeutics' ([[PRVL]] +1.2%) investigational AAV9 gene therapy, PR006 for the treatment of frontotemporal dementia with a GRN mutation (FTD-GRN)The Company expects to initiate enrollment in Phase 1/2 PROCLAIM trial of PR006 in next month, and anticipates to provide a biomarker and safety analysis on a subset of patients in the PROCLAIM trial in 2021.Earlier, the gene therapy received US Orphan Drug and Fast Track designation for the same indication.

For further details see:

Prevail's gene therapy Orphan drug in Europe for a type of dementia